Learn how Syngene developed an antiparasitic tablet for dogs containing multiple APIs (one of which is a very low dose) in just six months.

Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.

Learn how Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101, while ensuring high chiral purity of 98% during GMP manufacturing

How Syngene achieved cost minimization and quick turn-around time when scaling a client’s drug compound from lab-scale to cGMP-scale using the ‘SELECT’ criteria.

Learn how a partnership with a leading global biopharma for outsourced Bioanalytical studies for Large Molecule therapeutics evolved into a co-development partnership nearing a decade.

Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented, which enabled a mutully successful collaboration.

Learn how Syngene developed and commercialized for its client, a complex palatable dosage form comprising three actives for use in companion animals.

Read how Syngene’s partnership with a leading Biotech company working in the field  of cancer therapy, grew from one small pilot project to over  100 FTEs today.